Table 2. Summary of eMLST, monoclonal antibody typing and antibiotic susceptibility testing results for antibiotic-resistant P. acnes strains.

								rRNA mutation(s)		MICb
Isolate	Phylotype	Region	Source	Antibodytypinga	Allelic profile	eST	CC	16 S	23 S	TC	EM	CL	Erm(X)
PRP-062	IA1	Italy	Acne	IA	1-1-1-9-1-1-1-1	49	CC1	−	+ (2058)	32	≥256	32	–
308.2	IA1	Sweden	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	−	8	0.032	0.025	–
322.2	IA1	Sweden	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	−	8	≥256	1	–
401.5	IA1	Sweden	Acne	IA	1-1-1-3-1-1-1-2-2	3	CC3	+	+ (2057)	≥256	4	0.5	–
411.2	IA1	Sweden	Acne	IA	1-1-1-3-1-1-1-1	1	CC1	+	+ (2058)	8	≥256	16	–
413	IA1	Sweden	Acne	IA	1-1-1-3-1-1-17-33	88	S	+	−	8	0.032	0.032	–
416.1	IA1	Sweden	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	+ (2059)	8	≥256	2	–
423.1	IA1	Sweden	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	−	8	0.032	0.5	–
423.3	IA1	Sweden	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	−	8	0.032	0.25	–
425.1	IA1	Sweden	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	4	≥256	16	–
429.1	IA1	Sweden	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	-	8	0.5	0.5	–
R11883	IA1	UK	Blood	IA	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	6	≥256	32	–
R20767	IA1	UK	Pus	IA	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	6	≥256	8	–
PRP-002	IA1	Australia	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	8	≥256	8	–
PRP-003	IA1	UK	Acne	IA	8-1-1-3-1-1-2-2	43	CC3	+	−	24	<0.016	0.016	–
PRP-004	IA1	UK	Acne	IA	1-1-1-3-1-1-1-1	1	CC1	+	−	8	<0.016	0.023	–
PRP-053	IA1	Australia	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	3	≥256	1.5	–
PRP-101	IA1	USA	Acne	IA	1-1-1-3-1-1-2-2	3	CC3	+	+ (2059)	≥256	≥256	1.5	–
PRP-102	IB	USA	Acne	Atypical	1-1-1-4-1-4-8-21	42	CC5	+	+ (2059)	12	≥256	0.5	–
PV66	IC	UK	Acne	Atypical	9-1-5-8-6-8-14-6	85	S	+	+ (2058)	≥256	≥256	24	–
PRP-038	IC	UK	Acne	Atypical	9-1-4-8-6-8-14-14	70	S	+	+ (2059)	32	≥256	0.38	–
PRP-039	IC	UK	Acne	Atypical	9-1-4-8-6-8-14-14	70	S	+	+ (2059)	≥256	≥256	0.38	–
PRP-047	II	Greece	Acne	II	1-4-2-4-2-3-10-10	61	CC6	−	+ (2059)	0.25	≥256	2	–
PRP-078	IA1	Japan	Acne	IA	1-1-1-3-7-1-22-2	86	S	−	+ (2059)	0.125	≥256	24	–
434	IA1	Sweden	Acne	n/d	5-1-1-3-1-1-1-1	20	CC1	−	−	≥256	≥256	nd	–
226	IA1	Sweden	Acne	n/d	1-1-1-3-1-1-2-3	31	CC3	−	−	8	≥256	nd	–
HL097PA1	IC	USA	Acne	n/d	9-1-4-8-6-8-14-14	70	S	+	+ (2058)	nd	nd	nd	–
HL045PA1	IA1	USA	Acne	n/d	1-10-1-3-1-1-2-2	17	CC3	+	+ (2058)	16	≥256	≥256	–
HL007PA1	IA1	USA	Skin	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	24	≥256	≥256	–
HL038PA1	IA1	USA	Acne	n/d	1-1-1-3-1-1-2-4	10	CC3	+	+ (2059)	4	≥256	0.875	–
HL099PA1	IA1	USA	Acne	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	6	≥256	≥256	–
HL053PA1	IA1	USA	Acne	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	6	≥256	≥256	–
HL056PA1	IA1	USA	Skin	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	16	≥256	≥256	–
HL074PA1	IA1	USA	Skin	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	24	≥256	≥256	–
HL096PA2	IA1	USA	Skin	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	6	≥256	≥256	–
HL043PA1	IA1	USA	Acne	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	8	≥256	≥256	–
HL043PA2	IA1	USA	Acne	n/d	1-1-1-3-1-1-2-2	3	CC3	+	+ (2058)	3	≥256	≥256	–
HL072PA1	IA1	USA	Acne	n/d	1-1-1-3-1-1-1-1	1	CC1	+	+ (2058)	12	≥256	≥256	–
HL072PA2	IA1	USA	Acne	n/d	1-1-1-3-1-1-1-1	1	CC1	+	+ (2058)	6	≥256	≥256	–
HL005PA1	IA1	USA	Skin	n/d	1-1-1-3-1-1-5-2	11	CC3	+	+ (2058)	8	≥256	≥256	–

^aAntibody typing with type IA and type II monoclonal antibodies QUBPa1 and QUBPa2, respectively [12].

^bTetracycline resistance MIC≥1.0 mg/L; erythromycin resistance MIC≥0.5 mg/L; clindamycin resistance MIC ≥0.25 mg/L.